Kruppel-like factor 4 (KLF4) is a transcription factor that participates in both tumor suppression and oncogenesis. To determine the association of KLF4 with tumorigenesis, we integrated data assembled in the Oncomine database and discovered a decrease in KLF4 gene transcripts in breast cancers. Further analysis of the database also showed a correlation between KLF4 expression and estrogen receptor-a (ERa) positivity. Knockdown of KLF4 in MCF-7 cells elevated the growth rate of these cells in the presence of estrogen. Therefore, we examined the interaction between KLF4 and ERa, and found that KLF4 bound to the DNA-binding region of ERa. KLF4 thus inhibits the binding of ERa to estrogen response elements in promoter regions, resulting in a reduction in ERa target gene transcription. Earlier studies have reported that KLF4 is transcriptionally activated by p53 following DNA damage. We also showed that activation of p53 decreased the transcriptional activity of ERa by elevating KLF4 expression. Our studies discovered a novel molecular network between p53, KLF4 and ERa. As both p53 and ERa are involved in cell growth and apoptosis, these results may explain why KLF4 possesses both tumor suppressive and oncogenic functions in breast cancers.
Introduction
Kruppel-like factor 4 (KLF4/GKLF/EZF) encodes a transcription factor that is associated with both tumor suppression and oncogenesis (Evans and Liu 2008) . Several lines of evidence indicate that KLF4 is an important regulator of cell proliferation. Among the KLF4-regulated cell-cycle genes, many upregulated genes inhibit proliferation, whereas genes that promote proliferation are repressed (Mahatan et al., 1999; Shie et al., 1999 Nickenig et al., 2002; Chen et al., 2003) . This indicates that KLF4 regulates the expression of a set of cell-cycle genes to coordinately inhibit cellular proliferation. in vivo, KLF4 is essential for maintaining terminally differentiated epithelial cells in the lung, skin and gastrointestinal tract (Shields et al., 1996; Segre et al., 1999; Jaubert et al., 2003; Blanchon et al., 2006; Patel et al., 2006) . In cultured cells, KLF4 expression is temporally associated with conditions that promote growth arrest, such as serum deprivation, contact inhibition and DNA damage, and constitutive KLF4 expression inhibits DNA synthesis (Garrett-Sinha et al., 1996; Shields et al., 1996; Stone et al., 2002) . g-Irradiation increases KLF4 mRNA levels in a p53-dependent manner and similarly correlates with increased expression of p21 (Yoon et al., 2003) . It was further determined that KLF4 transactivates the p21 promoter by binding to a specific Sp-1-like cis-element in the proximal region of the promoter (Zhang et al., 2000) . Activation of p21 expression following DNA damage causes cell-cycle arrest at both the G1-S and G2-M transition points (Bissonnette and Hunting, 1998; Winters et al., 1998) . In addition to its effects on p21 expression, KLF4 has been reported to inhibit expression of cyclin D1 and cyclin B, which promote progression through the G1-S and G2-M boundaries, respectively (Shie et al., 1999 Yoon and Yang, 2004) . Thus, KLF4 has the potential to suppress tumor growth.
It was also shown that KLF4 suppresses p53 expression by directly acting on its promoter, thus providing resistance to DNA damage-induced apoptosis (Wei et al., 2007) . Depleting KLF4 from breast cancer cells restores p53 levels and causes p53-dependent apoptosis (Rowland et al., 2005) . In addition to p53 suppression, KLF4 has been reported to suppress apoptosis through the direct downregulation of the Bax promoter (Ghaleb et al., 2007) . Thus, the oncogenic potential of KLF4 appears to lie in its ability to inhibit apoptosis. Therefore, KLF4 could act as an oncogene in genetic contexts in which KLF4 inhibits apoptosis but does not induce cell-cycle arrest.
As KLF4 has pivotal roles in cell-cycle arrest and inhibition of apoptosis, it is logical to assume that KLF4 would have both tumor-suppressive functions and oncogenic potential. Consistent with this notion, KLF4 is downregulated in many human cancers, including esophageal, gastric, colorectal, bladder and prostate cancers, whereas it is overexpressed in primary breast ductal carcinomas and oral squamous cell carcinomas (Foster et al., 2000; Wang et al., 2002; Ohnishi et al., 2003; Luo et al., 2004) .
Breast cancer is typically a hormone-dependent tumor in which exposure to estrogen increases breast cancer incidence and proliferation (Key and Pike, 1988; Henderson et al., 1988; Pike et al., 1993; Dorgan et al., 1996) . Estrogens mediate their effects after binding to the estrogen receptors (ERs), ERa and ERb, which are members of the nuclear receptor superfamily that function as ligand-induced transcription factors (McKenna 2002; Mangelsdorf et al., 1995; Chambon, 1996; Tateishi et al., 2006) . On binding estrogen, the receptor ligand-binding domain undergoes a characteristic conformational change that induces receptor dimerization. The dimer then binds DNA to stimulate target gene expression. ERa activity is stimulated by two distinct regions, the activation function-1 and -2 domains; the latter domain is located in the ligand-binding domain and exerts ligand-dependent transcriptional activity (Tora et al., 1989) . Crystal structure analysis of the ERs and other nuclear receptors revealed 12 conserved helices within their ligand-binding domains (Shiau et al., 1998) . Helix 12, the C-terminal helix, forms the critical core (AD core) for the activation function-2 function of the receptor. This region has an important role in binding co-activators to the ligandbound receptor (Heery et al., 1997) .
Here, we performed an extensive analysis of the Oncomine database and showed that KLF4 expression was associated with breast cancer tumorigenesis. Analysis of the database also showed a correlation between KLF4 expression and ERa-positive breast cancers. in vitro experiments using the ERa-positive breast cancer cell line MCF-7 revealed that estrogen-dependent cell growth was significantly enhanced by knockdown of KLF4. Coimmunoprecipitation experiments revealed that KLF4 binds to the DNA-binding region of ERa and inhibits the binding of ERa to estrogen response elements (EREs) in promoter regions to reduce the transcription of ERa target genes. We also showed that activation of p53 decreased ERa transcriptional activity by elevating KLF4 expression. These results revealed the existence of a novel molecular network that includes p53, KLF4 and ERa. As both p53 and ERa are involved in cell growth and apoptosis, the genetic and epigenetic status of these factors may determine whether KLF4 acts as a tumor suppressor or oncogene in breast cancers.
Results and discussion
Several lines of evidences indicate that Kruppel-like factor 4 (KLF4/GKLF/EZF) regulates tumor progression. To confirm the relationship between KLF4 expression levels and breast cancer progression, we compared the expression levels of KLF4 in normal tissues and breast carcinomas using the Oncomine database, which provides publicly available data sets on cancer gene expression. Nine of the 11 data sets, which contain gene chip profiles classified as normal or breast carcinoma tissues, showed that KLF4 mRNA levels were lower in breast carcinomas than in normal tissues. We also compared the correlation between KLF4 mRNA levels and the breast cancer tumor grade using data sets containing gene chip profiles classified by tumor grade. Fifteen of the 20 data sets showed an inverse correlation between KLF4 expression levels and tumor grade. Representative results of two independent data sets characterized by large population sizes (Miller et al., 2005; Ivshina et al., 2006; Richardson et al., 2006; Finak et al., 2008) are shown in Figure 1a (KLF4 expression levels in normal versus breast carcinoma; P ¼ 5.4EÀ4, 7.0EÀ3) and 1b (KLF4 expression levels in breast cancers classified by grade; P ¼ 8.0EÀ11, 2.6EÀ10). Earlier reports have shown that 70% of breast carcinomas have elevated KLF4 expression and that increased nuclear staining for KLF4 is associated with a more aggressive phenotype (Foster et al., 2000; Pandya et al., 2004) . Inconsistencies between the results obtained from the Oncomine database and earlier reports may be due to the genetic or epigenetic context of breast cancer tissues.
Breast cancer typically depends on hormones. Estrogen binds to the ERa, which belongs to the nuclear receptor superfamily, and increases the incidence and proliferation of breast cancer. Furthermore, almost 60% of breast cancer tissues have higher ERa protein levels than normal tissues. Recently, several lines of evidence showed that the KLF family proteins are associated and interact with nuclear receptors (Shindo et al., 2002; Oishi et al., 2008) . Thus, we further examined the relationship between KLF4 and ERa in breast cancer tissues. We compared the correlation between KLF4 expression levels and ERa positivity using Oncomine data sets containing gene chip profiles classified by ERa positivity (Minn et al., 2005; Ivshina et al., 2006) . As shown in Figure 1c , there was a significant correlation between KLF4 expression levels and ERa positivity. These results raise the possibility that KLF4 and ERa coordinately regulate breast cancer progression.
To investigate the relationship between KLF4 and ERa in breast cancer growth, we used KLF4 small interfering RNAs (siRNAs) to knock down KLF expression in the ERa-positive breast cancer cell line, MCF-7. Both KLF4 siRNAs (siRNA nos. 1 and 2) effectively reduced KLF4 mRNA and protein levels (Figure 2a and b) in MCF-7 cells. Using these siRNAs, we examined the effect of KLF4 knockdown on the growth rate of MCF-7 cells. In the absence of estrogen, KLF4 knockdown did not affect the growth rate of MCF-7 cells (Figure 2c ). By contrast, in the presence of estrogen, the growth rate of MCF-7 cells increased and this estrogen-dependent enhancement of cell growth was further potentiated by KLF4 knockdown (Figure 2c ). These observations indicate that KLF4 suppresses estrogen-dependent breast cancer growth.
Estrogen enhances breast cancer growth by inducing transcriptional activity of ERa. Thus, we next examined To study the molecular mechanism for the inhibition of ERa-dependent transcription by KLF4, we examined KLF4 suppresses estrogen-dependent breast cancer K Akaogi et al the binding of KLF4 to ERa. In coimmunoprecipitation experiments, KLF4 associated with ERa in an estrogendependent manner (Figure 4a and b) . Next, to identify the regions of ERa responsible for KLF4 binding, we generated several ERa truncation mutants. Coimmunoprecipitation experiments indicated that the DNAbinding domain of ERa was necessary for KLF4 binding (Figure 4c) . These results raised the possibility that the binding of KLF4 to the DNA-binding region of ERa may abrogate the recruitment of ERa to the EREs in the promoter region and thereby decrease ERa-dependent transcription. To test this hypothesis, we performed a chromatin immunoprecipitation (ChIP) assay using an ERa-specific antibody. The ChIP assay confirmed that ERa bound to the promoter region of the endogenous pS2 gene in MCF-7 cells in an estrogendependent manner (Figure 4d, lane 4) . The levels of ERa bound to the pS2 promoter region were decreased by KLF4 overexpression (Figure 4d, lane 8) . By contrast, knockdown of endogenous KLF4 increased the levels of ERa bound to the pS2 promoter region (Figure 4e, lane  8) . To confirm that KLF4 does not bind to the promoter region of the pS2, we conducted ChIP assay using a KLF4-specific antibody. The ChIP assay revealed that KLF4 bound to the promoter region of the Lefty1 gene ( Figure 4f, lane 2) , as reported earlier (Nakatake et al., À8 M), cell extracts were prepared, immunoprecipitated with an anti-FLAG antibody and then immunoblotted with the indicated antibodies (upper three panels). Alternatively, whole cell extracts were immunoblotted with the indicated antibodies (lower three panels). (d, e) Attenuation of ERa binding to pS2 DNA by KLF4. (d) MCF-7 cells were treated with control (cont.) or expression plasmids of KLF4 (KLF4) and then cultured in the presence or absence of estrogen (E2; 10 À8 M). Chromatin immunoprecipitation (ChIP) assays were performed using the indicated antibodies. Immunoprecipitated DNA was analysed using quantitative PCR and pS2 primers. Samples were normalized to the IgG DNA. (e) MCF-7 cells were treated with control (si-cont.) or KLF4-specific (si-KLF4) RNAi and then cultured in medium with or without estrogen (E2; 10 À8 M). ChIP assays were performed using the indicated antibodies. Immunoprecipitated DNA was analysed using quantitative PCR and pS2 primers. Samples were normalized to the IgG DNA. (f) KLF4 does not bind to pS2 DNA. MCF-7 cells were cultured with or without estrogen (E2; 10 À8 M). ChIP assays were performed using the indicated antibodies. Immunoprecipitated DNA was analysed by quantitative PCR using Lefty1 and pS2 primers. Samples were normalized to the IgG DNA. These results indicate that KLF4 associates with the DNA-binding region of ERa and inhibits ERa from binding to the promoter region of target genes. Recent reports have shown an interaction between KLF4 and p53. KLF4 is transcriptionally activated by p53 following DNA damage and causes cell-cycle arrest by inducing transcription of p21. Conversely, KLF4 suppresses the expression of p53 by directly acting on its promoter, thereby causing resistance to DNA damageinduced apoptosis. Therefore, we compared KLF4 expression levels between wild-type and mutant p53-expressing breast cancers using the Oncomine data sets. As shown in Figure 5a , the expression levels of KLF4 in breast cancers expressing wild-type p53 were higher than those in breast cancers expressing a mutated p53 (Miller et al., 2005; Ivshina et al., 2006) . These results confirm an interaction between KLF4 and p53 in breast cancer tissues.
We next examined the effect of siRNA-mediated knockdown of endogenous p53 in MCF-7 cells on KLF4 levels. The siRNA for p53 effectively reduced p53 protein and mRNA levels. Treating MCF-7 cells with p53 siRNA also decreased KLF4 protein and mRNA levels, suggesting that p53 regulates the transcription of KLF4 (Figure 5b, c) . Earlier reports have shown that estrogen induces accumulation of wild-type p53 protein through ERa (Okumura et al., 2002) . Moreover, we and other groups have shown that p53 enhances KLF4 expression (Figures 5b and c; Zhang et al., 2000; Yoon et al., 2003; Yoon and Yang, 2004) . It is reasonable that ERa-positive tumors have higher levels of KLF4 than ERa-negative tumors (Figure 1c) .
Given that KLF4 suppresses the transcriptional activity of ERa (Figure 3) , it was possible that p53 knockdown enhances the transcriptional activity of ERa. Thus, we transfected a reporter plasmid containing ERE into MCF-7 cells with control or p53 siRNA. Figure 5 p53 reduces ERa-dependent transcription by upregulating KLF4 transcription. (a) Enhanced expression of KLF4 in wildtype p53 tumor tissues in two independent studies of human breast cancer (Miller et al., 2005; Ivshina et al., 2006) . Data and statistics were obtained from www.oncomine.org. (b, c) Decreased KLF4 protein levels by p53 knockdown. (b) Total RNA was isolated from control (si-cont.) or p53-specific (si-p53) siRNA-treated MCF-7 cells, and p53, KLF4 and ERa mRNA levels were quantified by realtime revere transcription (RT)-PCR. (c) Cell extracts were prepared from MCF-7 cells that were transfected with control small interfering RNA (siRNA) (si-cont.) or p53-specific siRNA (si-p53), and immunoblotted with the indicated antibodies (left panel). KLF4 protein levels were quantified. Bars represent means þ s.d. (n ¼ 3) (right graph). (d, e) Stimulation of ERa-dependent transcription by p53 knockdown. (d) A control (pGL3-basic) or luciferase reporter plasmid containing four tandem E2 response elements (ERE-luc) was transfected into MCF-7 cells that were treated with control (si-cont.) or p53-specific (si-p53) siRNA. Cell extracts derived from these cultures that were treated with or without estrogen (E2; 10 À8 M) were examined using luciferase assays. Bars represent means þ s.d. (n ¼ 3). (e) Total RNA was isolated from control (si-cont.) or p53-specific (si-p53)-treated MCF-7 cells and pS2 mRNA levels were quantified by real-time RT-PCR. Bars represent means þ s.d. (n ¼ 3). (f) Increased KLF4 protein levels by p53. MCF-7 cells treated with control (si-cont.) or KLF4-specific (si-KLF4) siRNA were UV irradiated (30 J/m 2 ), and the cell extracts were immunoblotted with the specified antibodies. (g) p53-induced reduction of ERa-dependent transcription through KLF4. A control (pGL3-basic) or luciferase reporter plasmid containing four tandem E2 response elements (ERE-luc) was transfected into MCF-7 cells that were treated with control (si-cont.) or KLF4-specific (si-KLF4) siRNA and then either left untreated or exposed to UV irradiation (30 J/m 2 ). Cell extracts derived from these cultures were examined using luciferase assays. Bars represent means þ s.d. (n ¼ 3).
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Knockdown of p53 by siRNA did not affect ERa protein and mRNA levels (Figures 5b and c) . However, the transcriptional activity of the reporter plasmids that was increased by estrogen treatment was further potentiated by p53 knockdown (Figure 5d ). Reverse transcription-PCR analysis showed that pS2 mRNA levels were upregulated by estrogen treatment and further increased by knockdown of p53 (Figure 5e ).
Next, we examined the effect of ultraviolet (UV) irradiation on the transcriptional activity of ERa, as UV irradiation induces the accumulation and activation of p53. We performed immunoblotting using a p53-specific antibody and confirmed the accumulation of p53 protein levels (Figure 5f ). Similar to the elevated p53 protein levels, UV irradiation also increased KLF4 protein levels (Figure 5f ). Treating the cells with the KLF4 siRNA effectively decreased KLF4 protein levels but did not affect p53 protein levels (Figure 5f ). In a transient transcription assay using reporter plasmids bearing EREs, the transcriptional activity of ERa induced by estrogen treatment was inhibited by UV irradiation (Figure 5g , compare lanes 7 and 8). Knockdown of endogenous KLF4 in MCF-7 cells partly recovered the transcriptional activity of ERa that was suppressed by UV irradiation (Figure 5g, compare lanes 8 and 9) . These results show that p53-dependent suppression of ERa transcriptional activity was mediated by KLF4.
Several lines of evidence suggest that there is cross-talk between p53 and ERa. ERa binds directly to p53 and represses its function Liu et al., 2006) . p53 and ERa dimers interfere with the ability of ERa to bind EREs and thereby inhibit ERa-dependent transcription Yu et al., 1997) . Consistent with the earlier reports, our observations indicate that the accumulation and activation of p53 abrogate the transcriptional activity of ERa. The result that KLF4 knockdown recovered p53-mediated suppression of ERa transcriptional activity suggests that, in addition to the direct inhibition of ERa transcriptional activity by p53, there is another pathway of cross-talk between p53 and ERa that involves KLF4 (Figure 6 ).
The results from the Oncomine database indicated that the KLF4 mRNA levels were lower in breast carcinomas than in normal tissues. In addition, the Oncomine analysis revealed that KLF4 expression levels were negatively correlated with the tumor grade. On the other hand, Ruppert's group showed that the mRNA and protein levels of KLF4 were higher in breast cancer tissues than in normal breast tissues (Foster et al., 2000; Pandya et al., 2004) . Rowland et al. (2005) recently reported that KLF4 simultaneously represses p53 levels and induces p21 CIP1 , the latter of which represents the dominant response, resulting in cell-cycle arrest. In the absence of p21 CIP1 or the presence of RAS V12 -cyclin-D1 signaling, KLF4 acts as a cell-cycle promoter by suppressing p53 expression. Here, we showed that KLF4 inhibits ERa target gene transcription in an estrogen-dependent manner and abrogates breast cancer cell growth. Moreover, p53 suppresses estrogen-dependent tumor growth by increasing KLF4 levels. Our data, along with earlier reports, indicate that there are at least three distinct KLF4 pathways that are associated with tumor suppression or oncogenesis (Supplementary Figure 1) . Thus, whether KLF4 acts as a tumor suppressor or oncogene is likely due to differences in the cell context, such as the expression patterns of ERa, p21 and p53 (Supplementary Figure 1 ). As the expression of these genes is regulated by genetic and epigenetic mechanisms, genetic and epigenetic alterations may determine whether KLF4 acts as a tumor suppressor or oncogene in breast cancers. Therefore, the differences between our results obtained from the Oncomine database (Figure 1a and b) and earlier reported data (Foster et al., 2000; Pandya et al., 2004) may be due to the differences in the expression pattern of ERa, p21 or p53.
Materials and methods
Cell culture and transfection MCF-7 human breast cancer cells that express wild-type p53 and 293 human kidney epithelial cells were maintained in Dulbecco's modified Eagle's medium (Sigma-Aldrich Corporation, St Louis, MO, USA). All media were supplemented with 10% fetal bovine serum and penicillin-streptomycin mixed solution (Nakarai tesque, Kyoto, Japan). Twenty-four hours before transfection, the medium changed to phenol red-free Dulbecco's modified Eagle's medium containing 4% charcoalstripped fetal bovine serum. The proliferation of cultured cells was measured by MTT assay using the MTT Cell Count Kit (Nakarai Tesque). Transfection was performed with PerFectin Transfection Reagent (Genlantis, San Diego, CA, USA), Lipofectamine LTX (Invitrogen, Carlsbad, CA, USA) and TransFast Transfection Reagent (Promega, Madison, WI, USA).
Expression vectors, antibodies
Complementary DNAs encoding full-length and various truncated forms of ERa were amplified by PCR and subcloned into the pcDNA3 plasmid (Invitrogen) containing sequences coding for FLAG sequences. Similarly, full-length KLF4 complementary DNA was cloned into the pCMV5 plasmid Luciferase reporter assay A 4 Â ERE-TATA-luc reporter plasmid has been described earlier (Tateishi et al., 2006) . Twenty-four hours after transfection, we replaced the culture medium with fresh medium containing ligands. Luciferase assays were performed on cell extracts according to the manufacturer's protocol (Promega). Individual transfections, each of which was performed in three wells, were repeated at least three times.
RNA interference
For transfection of siRNAs, cells at 30-50% confluency were transfected with 20 nm of siRNA using LipofectAmine RNAi max (Invitrogen) according to the manufacturer's protocol. All siRNAs were purchased from Invitrogen. The siRNA duplexes KLF4 no. 1; 5 0 -UGAGAUGGGAACUCUUUGUGUAG GU-3 0 , KLF4 no. 2; 5 0 -AUCGUUGAACUCCUCGGUCU CUCUC-3 0 , and p53; Validated Stealth RNAi. Stealth RNAi negative control was used as a negative control.
Coimmunoprecipitation and immunoblotting
Cells were lysed in TNE buffer (10 mm Tris-HCl (pH 7.8), 1% Nonidet P-40 (NP-40), 0.15 M NaCl, 1 mM EDTA, 1 M phenylmethylsulfonyl fluoride, 1 g/ml aprotinin). Extracted proteins were immunoprecipitated with antibody-coated protein G Sepharose (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) or anti-FLAG M2 agarose (Sigma-Aldrich Corporation) beads. Bound proteins were separated by sodium dodecyl sulfate-PAGE, transferred to polyvinylidine difluoride membranes (Millipore, Billerica, MA, USA) and detected with appropriate primary antibodies and horseradish peroxidaseconjugated secondary antibodies. Specific proteins were visualized using an enhanced chemiluminescence western blot detection system (GE Healthcare Bio-Sciences).
ChIP and real-time PCR detection
Chromatin immunoprecipitation assay was performed according to the published procedure (Murayama et al., 2008) . The primers for real-time PCR are forward: TATGAA TCACTTCTGGAGTG A; reverse: GAGCGTTAGATAACA TTTGCC for pS2 gene upstream region. Forward: GCCCAG ACAGACTTGCCCTATC; reverse: CAGGCAGCTGGATG TGCTGA for Lefty1gene upstream region.
Real-time reverse transcription-PCR Real-time reverse transcription-PCR was performed essentially as described earlier (Murayama et al., 2008) . Tissues and cells were homogenized in 1 ml of Isogen and total RNA was extracted according to the instruction manual (Nippon gene, Tokyo, Japan). Complementary DNA was synthesized from total RNA using Revatra Ace reverse transcriptase (Toyobo, Osaka, Japan) and oligo dT primer. Real-time PCRs were performed to amplify fragments representing the indicated mRNA expression. The primer sequences are as follows:
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